The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
 
Lajos Pusztai
Honoraria - Almac Diagnostics; AstraZeneca/MedImmune; Merck; Pfizer; pfizer; Syndax
Consulting or Advisory Role - H3 Biomedicine; Merck; Novartis; PierianDx; Seagen; Syndax
Research Funding - AstraZeneca; Genentech; Merck; Seagen
 
Erin Wysong Hofstatter
No Relationships to Disclose
 
Gina G. Chung
Research Funding - Millennium (Inst)
 
Nina Ruth Horowitz
No Relationships to Disclose
 
Donald R. Lannin
No Relationships to Disclose
 
Brigid K. Killelea
No Relationships to Disclose
 
Anees B. Chagpar
No Relationships to Disclose
 
Michael DiGiovanna
Research Funding - Cascadian Therapeutics (Inst); Genentech (Inst)
Patents, Royalties, Other Intellectual Property - DAKO - Royalties; NeoMarkers - Royalties
 
Courtney Frederick
No Relationships to Disclose
 
Trisha Burello
No Relationships to Disclose
 
Malini Harigopal
No Relationships to Disclose